Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management
- PMID: 33707912
- PMCID: PMC7922461
- DOI: 10.5005/jp-journals-10071-23733
Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management
Abstract
How to cite this article: B, Khanna P, Sarkar S. Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management. Indian J Crit Care Med 2021;25(2):242-244.
Keywords: COVID-19; Coronavirus disease; Pulmonary fibrosis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.
Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.
Conflict of interest statement
Source of support: Nil Conflict of interest: None
Similar articles
-
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat?Indian J Crit Care Med. 2021 Feb;25(2):245-246. doi: 10.5005/jp-journals-10071-23734. Indian J Crit Care Med. 2021. PMID: 33707913 Free PMC article.
-
Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We Stand?Indian J Crit Care Med. 2021 Jun;25(6):699-703. doi: 10.5005/jp-journals-10071-23855. Indian J Crit Care Med. 2021. PMID: 34316152 Free PMC article.
-
Eyes Have It: From COVID-19 Perspective.Indian J Crit Care Med. 2020 Nov;24(11):1139-1140. doi: 10.5005/jp-journals-10071-23644. Indian J Crit Care Med. 2020. PMID: 33384526 Free PMC article.
-
Basic Critical Care for Management of COVID-19 Patients: Position Paper of the Indian Society of Critical Care Medicine, Part II.Indian J Crit Care Med. 2020 Nov;24(Suppl 5):S254-S262. doi: 10.5005/jp-journals-10071-23593. Indian J Crit Care Med. 2020. PMID: 33354049 Free PMC article. Review.
-
Pathogenesis-directed therapy of 2019 novel coronavirus disease.J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33073355 Review.
Cited by
-
Potential "Therapeutic" Effects of Tocotrienol-Rich Fraction (TRF) and Carotene "Against" Bleomycin-Induced Pulmonary Fibrosis in Rats via TGF-β/Smad, PI3K/Akt/mTOR and NF-κB Signaling Pathways.Nutrients. 2022 Mar 5;14(5):1094. doi: 10.3390/nu14051094. Nutrients. 2022. PMID: 35268069 Free PMC article.
-
Pharmacological approaches to pulmonary fibrosis following COVID-19.Front Pharmacol. 2023 Jun 15;14:1143158. doi: 10.3389/fphar.2023.1143158. eCollection 2023. Front Pharmacol. 2023. PMID: 37397477 Free PMC article. Review.
-
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.Inflammopharmacology. 2022 Dec;30(6):2017-2026. doi: 10.1007/s10787-022-01027-6. Epub 2022 Aug 31. Inflammopharmacology. 2022. PMID: 36044102 Free PMC article. Review.
-
Tocotrienol-Rich Fractions Offer Potential to Suppress Pulmonary Fibrosis Progression.Int J Mol Sci. 2022 Nov 18;23(22):14331. doi: 10.3390/ijms232214331. Int J Mol Sci. 2022. PMID: 36430808 Free PMC article.
-
A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview.Front Pharmacol. 2024 May 9;15:1329743. doi: 10.3389/fphar.2024.1329743. eCollection 2024. Front Pharmacol. 2024. PMID: 38783956 Free PMC article. Review.
References
-
- Thille AW, Esteban A, Fernández-Segoviano P, Rodriguez JM, Aramburu JA, Vargas-Errázuriz P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diff use alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med. 2013;1(5):395–401. doi: 10.1016/S2213-2600(13)70053-5. DOI: - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous